Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Massachusetts General Hospital · Vall d'Hebron Institute of Oncology · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
648
total citations
- FWCI
- 59.07
- Percentile
- 100%
- References
- 32
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- ROS1
- Medicine
- Anaplastic lymphoma kinase
- Clinical endpoint
- Internal medicine
- ALK inhibitor
- Crizotinib
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- NFNational Foundation for Cancer Research
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- APAriad Pharmaceuticals
- CCelgene
- ABArray BioPharma
- RPRegeneron Pharmaceuticals
- MTMirati Therapeutics
- IIncyte
- CBCalithera Biosciences
- NINational Institutes of Health
- GGenentech
- ESEMD Serono
- IIgnyta
- FMFoundation Medicine
- NCNational Cancer InstituteAward: 5R01CA164273
- DSDaiichi Sankyo Europe